---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-283906"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2026-06-26T11:15:32+00:00"
generated_at: "2026-06-26T11:20:22.292699+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Jade Biosciences appoints Mark Eisner, former Vir CMO, to Board of Directors

## Summary
- Mark Eisner appointed as Class I director effective June 25, 2026; joins Nominating and Corporate Governance Committee.
- Eisner most recently EVP & CMO at Vir Biotechnology; previously CMO at Sonoma Biotherapeutics and FibroGen, and 11 years at Genentech/Roche.
- Received option for 47,675 shares vesting over 3 years; eligible for annual cash retainer under non-employee director program.

## SEC filing metadata
- accession: 0001193125-26-283906
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2026-06-26T11:15:32+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000119312526283906/0001193125-26-283906-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000119312526283906/d127137d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-283906
- JSON: https://secwatch.observer/filing/0001193125-26-283906.json
- Plain text: https://secwatch.observer/filing/0001193125-26-283906.txt

## Key facts
- Executive change
  Mark Eisner was appointed as Class I director at Jade Biosciences, Inc..
  - Action: appointed
  - Role: Class I director
  source text: On June 25, 2026, the Board of Directors (the “Board”) of Jade Biosciences, Inc. (the “Company”) appointed Mark Eisner, M.D., M.P.H., to serve as a Class I director of the Company, to hold office until the Company’s 2028 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier resignation, death or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1798749/000119312526283906/0001193125-26-283906-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.